Claudia Provenzano
Rome, 00015, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
circARHGAP10 as a candidate biomarker and therapeutic target in myotonic dystrophy type 1.
Journal: Molecular therapy. Nucleic acids
Published: October 31, 2024
Muscle-specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1.
Journal: Clinical and translational medicine
Published: July 31, 2024
Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing.
Journal: International journal of molecular sciences
Published: March 29, 2022
Time-controlled and muscle-specific CRISPR/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene.
Journal: Molecular therapy. Nucleic acids
Published: August 18, 2021
Design of novel small molecule base-pair recognizers of toxic CUG RNA transcripts characteristics of DM1.
Journal: Computational and structural biotechnology journal
Published: September 20, 2020
High-throughput analysis of the RNA-induced silencing complex in myotonic dystrophy type 1 patients identifies the dysregulation of miR-29c and its target ASB2.
Journal: Cell death & disease
Published: March 15, 2018
CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients.
Journal: Molecular therapy. Nucleic acids
Published: August 07, 2017
Functional characterization of two novel mutations in TTF-1/NKX2.1 homeodomain in patients with benign hereditary chorea.
Journal: Journal of the neurological sciences
Published: September 04, 2015
MiR-21 is an Ngf-modulated microRNA that supports Ngf signaling and regulates neuronal degeneration in PC12 cells.
Journal: Neuromolecular medicine
Published: August 20, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026